Study treatment schema and flowchart. (A) The study schema. Treatment consisted of standard dose CHOP given on day 1 of each cycle for 6 cycles. Oral azacitidine (CC-486) at 300 mg daily was administered for 7 days before cycle 1 of CHOP, and for 14 days before CHOP cycles 2 to 6. Growth factor such as pegfilgrastim was mandatory after CHOP. (B) The study flowchart. Of the 21 patients enrolled, 20 completed 3 cycles of study treatment, and 18 completed 6 cycles. Ten patients received consolidative SCT. EOT, end of treatment.